Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for hemophilia and rare diseases, raised $159 million by offering 8.8 million shares at $18, the high end of the range of $16 to $18. The Stevenage, UK-based company offered 1.5 million more shares than anticipated. At pricing, Freeline Therapeutics commands a fully diluted market value of $636 million.
Freeline Therapeutics plans to list on the Nasdaq under the symbol FRLN. J.P. Morgan, Morgan Stanley, Evercore ISI and Wedbush PacGrow acted as lead managers on the deal.
